November 17, 2020
First Commercial Use in United States of Medtronic’s Abre Venous Stent Performed at Sanger Vascular & Heart Institute
November 17, 2020—Atrium Health Sanger Heart & Vascular Institute in Charlotte, North Carolina, announced that Erin Murphy, MD, Director of the Sanger’s Venous and Lymphatic Program, performed the first commercial procedure in the United States with the Abre venous self-expanding stent system (Medtronic) at Atrium Health Pineville.
In the first commercial case, Dr. Murphy’s team implanted the stent to treat a left iliac vein occlusion, which was causing pain, swelling, open sores, and decreased circulation in the patient’s leg. After the procedure, the patient is reported to be thriving, with improved skin conditions attributed to increased circulation and markedly decreased swelling, according to the Sanger announcement. The press release also includes a profile of one of Dr. Murphy’s patient's experience with venous disease and her successful treatment in the ABRE study.
On October 26, Medtronic announced FDA approval of the Abre device, which is indicated for use in the iliofemoral veins in patients with symptomatic iliofemoral venous outflow obstruction. In Europe, Abre received CE Mark approval in April 2017.
Dr. Murphy served as the global coprincipal investigator of Medtronic’s ABRE investigational device exemption clinical study, which supported FDA approval of the device. Dr. Murphy and Gregory Stanley, MD, vascular surgery fellowship director at Sanger, enrolled and treated the first patient in the world in the study in December 2017.